Lupin stock dives 3% after Q3 earnings, PAT comes at Rs545.5cr

4 Feb 2022 , 11:57 AM

Lupin stock was under pressure on Friday after announcing December 2021 (Q3FY22) quarter earnings. Lupin posted a consolidated profit of Rs545.5cr in Q3FY22 against a profit of  Rs438.3cr in Q3FY21. The company had posted a loss of Rs2,098cr in Q2FY22.

Consolidated revenue stood at Rs4,160.9cr in the quarter under review, rising from Rs4,017.4cr in Q3 of last fiscal and Rs4,091.3cr of the preceding quarter.

Nilesh Gupta, Managing Director, Lupin Limited said, “We are on the path of sustained growth across markets. Our inhalation portfolio continues to build share in the U.S. and helped register double-digit growth sequentially, despite pricing and demand challenges on seasonal products. The inflationary environment has impacted margins, but we remain focussed on margin and EBIDTA improvement as we deliver on key product launches, cost optimization and improving efficiencies, especially by H2 FY23”

Key highlights of Q3 are:

• Personnel cost was 18.2% of sales at Rs743.8cr compared to Rs758.6cr in Q2 FY2022
• Manufacturing and other expenses were 33.1% of sales at Rs1,351.8cr compared to Rs1,142.5cr in Q2 FY2022
• The financial results include one-time expenses of Rs193.2cr, excluding which the EBIDTA (before Fx and Other income) was 13.7% of sales
• Investment in R&D for the quarter was Rs354.6cr (8.7% of sales)
• Operating working capital was Rs6,568cr as of December 31, 2021
• Capital Expenditure for the quarter was Rs278.7cr and Rs529.5cr for 9M FY2022
• Net Debt as of December 31, 2021, stands at Rs2,244.8cr
• Net Debt-Equity for the company as of December 31, 2021, stands at 0.18

At around 11.54 am, Lupin was trading at Rs875.50 per piece down by 2.7% on Sensex. The stock has touched an intraday high and low of Rs900 per piece and Rs863.60 per piece respectively.